Preliminary studies have found that two non-psychoactive cannabinoids can induce necrosis in human gastrointestinal cancer cells.

Cannabics Pharmaceuticals, an American medical cannabis firm with an Israeli R&D department, recently released the results of a pre-clinical trial suggesting that the cannabinoids CBC (cannabichromene) and CBG (cannabigerol) can help destroy tumors. The tests, which were conducted at the company's High Throughput Screening (HTS) lab facilities in Israel, found that CBC and CBG can induce significantly higher rates of necrosis in human gastrointestinal cancer cells compared to other cannabinoids.